背景:尽管甲状腺淋巴瘤是一种罕见的恶性疾病,对于颈部肿块增大的患者,仍需考虑。原发性甲状腺淋巴瘤(PTL)可以通过化学免疫疗法治愈,而无需甲状腺切除术。从而避免手术并发症以及激素替代疗法。
目的:该研究旨在评估临床特征,危险因素,和PTL的治疗结果。
方法:回顾性研究。
方法:本研究在曼苏拉大学肿瘤中心进行。
方法:该研究包括13名PTL患者(4名男性和9名女性),中位年龄为58岁[范围,43-73年]。
方法:患者接受以利妥昔单抗±蒽环类为基础的方案治疗。
方法:显示PTL患者的临床病理特征。
结果:在这项研究中,9例(69.3%)通过细针穿刺活检和芯针活检确诊,1例患者(7.7%)通过半甲状腺切除术,甲状腺全切除术3例(23%)。演讲的共同阶段是早期阶段,包括7名患者(53.8%),其次是高级阶段,包括6名患者(46.2%)。3例患者(23.07%)有桥本甲状腺炎病史。两名患者(15.4%)的丙型肝炎病毒检测呈阳性。1例患者(7.7%)有类风湿性关节炎。一名患者患有甲状腺癌和甲状腺淋巴瘤的双重恶性肿瘤。8例患者(61.6%)呈现高-中、高国际预后指数风险。4名患者(30.8%)达到完全缓解,中位无病生存期为20.58个月.中位总生存期为11.5个月(范围:2.03-126.03个月)。
结论:多学科医师团队的合作,外科医生,病理学家需要早期检测PTL,并通过显著改进诊断和治疗策略来提高其预后.
BACKGROUND: Although thyroid lymphoma is an uncommon malignant disease, it is still important to consider in patients with an enlarging neck mass. Primary thyroid lymphoma (PTL) can be cured with chemoimmunotherapy without thyroidectomy, thus avoiding surgical complications as well as hormonal replacement therapy.
OBJECTIVE: The study aims to evaluate the clinical features, risk factors, and treatment outcomes of PTL.
METHODS: Retrospective study.
METHODS: The study was carried out in the Oncology Center of Mansoura University.
METHODS: The study included 13 PTL patients (4 male and 9 female) with a median age of 58 years [range, 43-73 years].
METHODS: The patients were treated with rituximab ± anthracycline-based regimens.
METHODS: Demonstration of the clinicopathological features of PTL patients.
RESULTS: In this study, 9 patients (69.3%) were diagnosed by fine-needle aspiration and core needle biopsy, 1 patient (7.7%) by hemithyroidectomy, and 3 patients (23%) by total thyroidectomy. The common stage of presentation was early stage, comprising 7 patients (53.8%), followed by advanced stage, comprising 6 patients (46.2%). Three patients (23.07%) had a history of Hashimoto\'s thyroiditis. Two patients (15.4%) tested positive for hepatitis C virus. One patient (7.7%) had rheumatoid arthritis. One patient had a double malignancy in the form of thyroid carcinoma and thyroid lymphoma. Eight patients (61.6%) presented with high-intermediate and high International Prognostic Index risk. Four patients (30.8%) achieved completed remission, and the median disease-free survival was 20.58 months. The median overall survival was 11.5 months (range: 2.03-126.03 months).
CONCLUSIONS: The cooperation of a multidisciplinary team of physicians, surgeons, and pathologists is necessary to detect PTL early and enhance its outcome through significant improvement of diagnostic and therapeutic strategies.